Humira
Late-stage successes for Amgen and Roche
February 5, 2015Sales and Marketing Amgen, Bendamustine, Gazyva, Genentech, Humira, Levact, Napp, Roche, adalimumab, obinutuzumab
Roche and Amgen have both posted successful late-stage trial results that they say will contribute to their applications for regulatory …
Sandoz earns historic first FDA biosimilar vote
January 8, 2015Sales and Marketing FDA, Humira, Novartis, Sandoz, Zarxio, filgrastim, zarzio
Sandoz has taken a huge step forward in the race to be the first company to market a biosimilar in …
Humira biosimilar released in India
December 18, 2014Research and Development, Sales and Marketing Humira, India, Zydus Cadila, anti-inflammatory, arthritis, bioscience
Indian firm Zydus Cadila has launched the first biosimilar of AbbVie’s anti-inflammatory medicine Humira, the world’s biggest-selling drug. Used as …
EMA responds to redaction concerns
November 14, 2014Sales and Marketing AbbVie, EMA, Goldacre, Humira, Rasi, adalimumab, redactions, transparency
The EMA has published a response to European Ombudsman Emily O’Reilly’s questions about some of its trial data redactions. O’Reilly’s …
AbbVie financials beat expectations
October 31, 2014Sales and Marketing AbbVie, Abbott, Creon, Humira, Iopinavir/ritonavir, Kaletra, Q3, Synthroid, levothyroxine, pancrelipase
AbbVie has announced higher-than-expected financial results for the third quarter of 2014, although it continues to rely heavily on blockbuster …
AbbVie agrees to buy Shire for £32bn
July 18, 2014Sales and Marketing AbbVie, Abbott, Humira, Shire, merger, new abbvie, takeover
Shire has accepted a £32 billion takeover deal from AbbVie after months of rejections and uncertainty. The firm, which is …
AbbVie a step closer to Shire takeover
July 14, 2014Sales and Marketing ADHD, AbbVie, Abbott, Humira, Shire, hep C, takeover
Shire is recommending a new offer from suitor AbbVie that could finally see the US giant merge with the Dublin-based …
AbbVie spells out Shire benefits
June 26, 2014Sales and Marketing ADHD, AbbVie, Abbott, Humira, Shire, merger
AbbVie has spelt out exactly why it believes that Shire should accept its $46.5 billion bid. The US firm wants …
EMA changes ‘on screen’ data policy
June 16, 2014Medical Communications, Research and Development, Sales and Marketing AbbVie, EMA, Goldacre, Humira, alltrials, transparency
The European Medicines Agency is to formally agree its policy on the vexed issue of the publication of clinical trial …
Humira drives AbbVie again
April 28, 2014Sales and Marketing AbbVie, Abbott, Humira, RA
Rheumatoid arthritis treatment Humira has once more driven AbbVie, bringing in more than half the company’s sales in the first …
AbbVie ‘pleased’ with first year
February 3, 2014Sales and Marketing AbbVie, Abbott, CLL, EMA, HIV, Humira
Rheumatoid arthritis treatment Humira – as expected – has driven AbbVie in its first year as a standalone company, accounting …
Orencia matches Humira
June 13, 2013Sales and Marketing AbbVie, Abbott, Humira, Orencia, RA
Bristol-Myers Squibb is hoping its biologic Orencia can grab a little more of the rheumatoid arthritis market after demonstrating non-inferiority …
Pfizer’s Xeljanz rejected in Europe
April 28, 2013Sales and Marketing CHMP, Humira, Pfizer, RA, Xeljanz, rheumatoid arthritis
Pfizer has suffered a major setback with the rejection of its new arthritis drug in Europe.The EMA’s medicines committee the …
AbbVie guards Humira data
March 13, 2013Sales and Marketing AbbVie, Abbott, Humira, RA, transparency
AbbVie has issued two injunctions against the European Medicines Agency to prevent the regulator revealing data about rheumatoid arthritis drug …
AbbVie splits from Abbott
January 7, 2013Sales and Marketing AbbVie, Abbott, HIV, Humira
AbbVie, the new $18 billion biopharma company which includes many of Abbott’s most high profile products, has finally launched. Abbott …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
